Klea Holding says H1 FY26 EBITDA totals AED 10.4 million; revenue drops 25% to EUR 8.6 million

  • Klea Holding estimated Smart Salem EBITDA at AED 10.4 million (about EUR 2.4 million), staying profitable through H1 2026.
  • Consolidated revenue fell 25% to EUR 8.6 million in H1 2026.
  • Medical Fitness segment revenue dropped 33% to EUR 6.9 million, while Health & Wellness tests and other segments climbed 65% to EUR 1.4 million.
  • Management flagged a sharp March slump tied to the Middle East conflict, with sequential monthly recovery from April and June revenue up year-on-year.
  • Outlook stays positive for H2 2026, citing continued rebound expectations and higher profitability on cost controls, new centers, and Klea Pharmaceuticals’ commercial launch.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Klea Holding published the original content used to generate this news brief on July 15, 2026, and is solely responsible for the information contained therein.

This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.